UroGen Pharma Ltd. (NASDAQ:URGN) to Post FY2026 Earnings of $1.59 Per Share, Jefferies Financial Group Forecasts

UroGen Pharma Ltd. (NASDAQ:URGNGet Rating) – Equities researchers at Jefferies Financial Group lowered their FY2026 earnings estimates for shares of UroGen Pharma in a report issued on Wednesday, May 11th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will earn $1.59 per share for the year, down from their prior forecast of $1.68.

Several other research firms also recently commented on URGN. HC Wainwright dropped their target price on UroGen Pharma from $34.00 to $26.00 in a research report on Tuesday, March 22nd. The Goldman Sachs Group raised their price objective on UroGen Pharma from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 22nd. Berenberg Bank started coverage on UroGen Pharma in a research report on Wednesday, April 27th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Zacks Investment Research downgraded UroGen Pharma from a “hold” rating to a “sell” rating in a research report on Friday, May 6th.

UroGen Pharma stock opened at $6.03 on Thursday. The company has a market capitalization of $126.03 million, a PE ratio of -1.22 and a beta of 1.41. UroGen Pharma has a 12 month low of $5.61 and a 12 month high of $19.66. The stock has a 50-day moving average price of $7.87 and a two-hundred day moving average price of $9.57.

UroGen Pharma (NASDAQ:URGNGet Rating) last posted its earnings results on Monday, March 21st. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.09). The firm had revenue of $16.17 million during the quarter, compared to the consensus estimate of $16.15 million. UroGen Pharma had a negative net margin of 230.67% and a negative return on equity of 256.66%.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its holdings in UroGen Pharma by 0.9% in the fourth quarter. BlackRock Inc. now owns 1,728,094 shares of the company’s stock worth $16,434,000 after purchasing an additional 15,871 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in UroGen Pharma in the fourth quarter worth approximately $9,754,000. RTW Investments LP bought a new stake in UroGen Pharma in the third quarter worth approximately $14,423,000. Great Point Partners LLC bought a new stake in UroGen Pharma in the third quarter worth approximately $12,615,000. Finally, Horton Capital Management LLC increased its holdings in UroGen Pharma by 9.0% in the third quarter. Horton Capital Management LLC now owns 684,749 shares of the company’s stock worth $11,517,000 after purchasing an additional 56,674 shares in the last quarter.

About UroGen Pharma (Get Rating)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Recommended Stories

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.